https://orcid.org/0000-0003-2446-649X
References
- Mahendraratnam N, Eckert J, Mercon K, et al. Understanding the Need for Non-Interventional Studies Using Secondary Data to Generate Real-World Evidence for Regulatory Decision Making, and Demonstrating Their Credibility. 2019. Available from: https://healthpolicy.duke.edu/sites/default/files/u31/non-interventional_study_credibility_0.pdf. Accessed February 25, 2020.
- U.S. Food and Drug Administration. Draft Guidance: Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices. Draft Guidnace for Industry and Food and Drug Administration Staff; 2017. Available from: https://www.fda.gov/downloads/medicaldevices/%0Adeviceregulationandguidance/guidancedocuments/ucm513027. Accessed February 25, 2020.
- Rao S, Hess C, Barham B, et al. A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial. JACC Cardiovasc Interv. 2014;7(8):857–867. doi:10.1016/j.jcin.2014.04.007
- Clincaltrials.gov. Micra Transcatheter Pacing System Post-Approval Registry.
- Lowenstern A, Lippmann SJ, Brennan JM, et al. Use of medicare claims to identify adverse clinical outcomes after mitral valve repair. Circ Cardiovasc Interv. 2019;12(5):e007451. doi:10.1161/CIRCINTERVENTIONS.118.007451
- Hlatky MA, Ray RM, Burwen DR, et al. Use of medicare data to identify coronary heart disease outcomes in the Women’s Health Initiative (WHI). Circ Cardiovasc Qual Outcomes. 2014;7(1):157–162. doi:10.1161/CIRCOUTCOMES.113.000373
- Roberts PR, Clementy N, Al Samadi F, et al. A leadless pacemaker in the real-world setting: the micra transcatheter pacing system post-approval registry. Hear Rhythm. 2017;14(9):1375–1379. doi:10.1016/j.hrthm.2017.05.017
- El-Chami M, Al-Samadi F, Clementy N, et al. Updated performance of the Micra transcatheter pacemaker in the real-world setting: A comparison to the investigational study and a transvenous historical control. Hear Rhythm. 2018;15(12):1800–1807. doi:10.1016/j.hrthm.2018.08.005
- Brouwer ES, Napravnik S, Eron JJJ, et al. Validation of medicaid claims-based diagnosis of myocardial infarction using an HIV clinical cohort. Med Care. 2015;53(6):e41–e48. doi:10.1097/MLR.0b013e318287d6fd
- Wahl PM, Rodgers K, Schneeweiss S, et al. Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf. 2010;19(6):596–603. doi:10.1002/pds.1924
- Bush M, Sturmer T, Stearns SC, et al. Position matters: validation of medicare hospital claims for myocardial infarction against medical record review in the atherosclerosis risk in communities study. Pharmacoepidemiol Drug Saf. 2018;27(10):1085–1091. doi:10.1002/pds.4396
- Ammann EM, Schweizer ML, Robinson JG, et al. Chart validation of inpatient ICD-9-CM administrative diagnosis codes for acute myocardial infarction (AMI) among intravenous immune globulin (IGIV) users in the sentinel distributed database. Pharmacoepidemiol Drug Saf. 2018;27(4):398–404. doi:10.1002/pds.4398
- Kucharska-Newton AM, Heiss G, Ni H, et al. Identification of heart failure events in medicare claims: the Atherosclerosis Risk in Communities (ARIC) Study. J Card Fail. 2016;22(1):48–55. doi:10.1016/j.cardfail.2015.07.013